Biodesix Inc Dossier
Qualitative Analysis
Business overview
Biodesix, Inc. (Nasdaq: BDSX) is a leading diagnostic solutions company specializing in personalized medicine for lung diseases. The company develops and commercializes blood-based diagnostic tests that assist physicians in early lung cancer detection, risk assessment, and treatment guidance. Its core diagnostic portfolio includes the Nodify Lung nodule risk assessment testing strategy (comprising the Nodify XL2 and Nodify CDT tests) and the IQLung treatment guidance strategy (comprising the GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests). Additionally, Biodesix provides custom Development Services to biopharmaceutical, life sciences, and research institutions to facilitate biomarker discovery, assay design, and clinical trial testing.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the dedicated sales force by hiring approximately six additional sales representatives per quarter to reach a target of 120 representatives by the end of 2026, with a focus on driving test volumes for Nodify Lung and GeneStrat tests in primary care and community oncology settings.
Expected impact: Aims to capture a larger share of the $27 billion U.S. lung disease diagnostic market and drive lung diagnostic testing revenue to $98 million in 2026.
Growing the Development Services offering by executing on existing biopharma contracts and securing new agreements for diagnostic discovery, clinical trial testing, and companion diagnostic development.
Expected impact: Provides high-margin, non-dilutive revenue streams; Development Services revenue doubled year-over-year in Q1 2026 to $3.3 million.
Improving operational efficiency and leverage by optimizing testing workflows, reducing cost per test, and enhancing revenue cycle management to achieve sustained Adjusted EBITDA profitability.
Expected impact: Helped achieve the first-ever positive Adjusted EBITDA quarter in Q4 2025 and narrowed Q1 2026 net loss by 30% year-over-year.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Biodesix will lead the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays utilizing Bio-Rad's Droplet Digital PCR (ddPCR) technology on the QX600 platform. The initial focus is on the ddPLEX ESR1 Mutation Detection Assay for breast cancer monitoring.
Terms: Biodesix will manufacture and distribute dedicated specimen collection kits for the developed assays following regulatory clearance, and will seek reimbursement through the Centers for Medicare & Medicaid Services (CMS).